Sulphonylureas and Glitazones In spite of the big number of anti-diabetic factors obtainable.

Slides:

Advertisements

Similar presentations

Oral Hypoglycemic Drugs And Classifications

Advertisements

Drug - treatment of Type 2 diabetes mellitus Oral antidiabetics as. MUDr. Pavlína Piťhová.

Current Management of Type 1 and Type 2 Diabetes Thomas Donner, M.D. Division of Endocrinology & Metabolism.

Katee Lira, PharmD PGY2 Ambulatory Care Pharmacy Resident

Antidiabetic Drugs Until 1994, FDA-approved antidiabetics Insulin and Sulfonylurea Last few years, the list was expanding Insulin (different preparations.

Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment.

Oral Medications to Treat Type 2 Diabetes

Combination Therapy in Type 2 Diabetes

S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.

LONG TERM BENEFITS OF ORAL AGENTS

IMPLICATIONS OF UKPDS GSK Advisory Board 24 May 2003 Dr. J. R. Conway.

Goals: 1) Understand the mechanism for ↑LDL in Type II diabetes 2) Having previously established the link between endothelial cell damage (loss of inhibitory.

Control of Energy The Original Biofuels. Importance of Glucose Regulation Too little – Brain problems Too much –Osmotic water loss (cellular and systemic)

By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.

oral hypoglycemic agents

Oral Hypoglycemic Drugs

Type 2 diabetes and cardiovascular disease Christopher D. Byrne FRCPath FRCP PhD Professor of Endocrinology & Metabolism Director of Wellcome Trust Clinical.

Reem Sallam, MD, MSc. PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.

Dr. Amr S. Moustafa, MD, PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.

cardio protection: Focus on

Focus On OBESITY, METABOLISM, AND DISEASE RISK. Obesity and Disease Risk Copyright 2012, John Wiley & Sons Canada, Ltd.

Oral hypoglycemic drugs

1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.

DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP.

- The Wonderful Hormone - INSULIN By Jeremy Wynn Cell Physiology.

PPAR gamma system and glucose: metabolism. Shared metabolic abnormalities with insulin resistance and endothelial dysfunction Glucotoxicity Lipotoxicity.

The Diabetic Athlete: Implications, participation Jason Blackham, MD August 21, 2008 Sports Medicine Rounds.

Metabolic Syndrome By: Dr.AP.Ahmed el-Shaer Dr.Mohamed El-Zayat.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.

+ Metformin and other antidiabetic agents in renal failure patients Kidney International (2015) 87, 308–322 Jean-Daniel Lalau,Paul Arnouts, Adnan Sharif.

Diabetes. The Food You Eat is Broken Down Into Glucose to Supply Energy to Your Cells.

Vascular effects of PPAR  activation: Inflammation.

Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.

Diabetes mellitus.

Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.

Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.

Endocrine system (endo) within; as apposed to outside the body

Endocrine Block 1 Lecture Dr. Usman Ghani

بسم الله الرحمن الرحيم.

Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS

Metabolic Changes in Diabetes Mellitus

Lecture on Anti Diabetic Drugs

The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes Cardiorenal Med 2011;1:211–219 -

Metabolic Changes in Diabetes Mellitus

Diabetes Mellitus Nursing Management.

Insulin action is reduced in obesity

Oral hypoglycemic drugs

Endocrine Block 1 Lecture Dr. Usman Ghani

Istanbul Medeniyet University

המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.

Diabetic Disorders 4th Leading cause of deaths in the US

oral hypoglycemic agents

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

PPARα: Savior or savage?

Nat. Rev. Endocrinol. doi: /nrendo

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

What do I remember? What is the effect of chronically elevated blood glucose levels on blood vessels? What cardiovascular diseases are a consequence of.

Figure 1 Simplified representation of the physiological

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

Treating Diabetes by Blocking a Vascular Growth Factor

A working hypothesis for insulin action in the brain.

Unit 1 Cells and Proteins Advanced Higher Biology Miss Aitken

Defective response to insulin secretagogues may arise from A) decreased concentrations of a given secretagogue, B) loss of β-cell responsiveness to that.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Type 2 Diabetes Story and Treatment For a long time, dietary fat has been recognized a potentially essential modifiable risk agent for diabetes.

Oral Antihyperglycemic Agents In the UKPDS, developed glycemic dominance, irrespective of the factor utilized (metformin, sulfonylureas, or insulin)

Postoperative blood glucose levels and total insulin requirement.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

Sulphonylureas and Glitazones In spite of the big number of anti-diabetic factors obtainable

Sulfonylurea medicines link the sulfonylurea receptor

What's more, Sulfonylureas are strong, glucose-independent insulin secretagogues

The initial-descent sulfonylureas are actually the oldest

The second-descent sulfonylureas

Regardless of the beneficial impacts of metformin in developing glycemic control

Oftentimes, as well, glycemic control damages in patients treated with metformin

Glitazones Glitazones develop insulin work in adipose, muscle, and hepatic tissue

Stimulation of PPAR-γ produces in a great number of both vascular and metabolic impacts

Glitazones also decrease blood pressure, develop lipid metabolism